CJC-1295 + DAC
CJC-1295 with DAC Product Description — Research Use Only
CJC-1295 with DAC is a synthetic research peptide analog of growth hormone-releasing hormone, commonly known as GHRH. The DAC, or drug-affinity-complex, is designed to extend the peptide’s activity by allowing it to bind to circulating albumin, making it longer acting than non-DAC GHRH analogs.
Research on CJC-1295 with DAC has most commonly focused on growth hormone signaling, IGF-1 pathway activity, pituitary response, extended peptide activity, metabolic research, recovery-related pathways, and body-composition markers. Published studies describe CJC-1295 as a long-acting GHRH analog associated with increased growth hormone and IGF-1 activity while maintaining pulsatile growth hormone secretion patterns.
CJC-1295 with DAC is commonly studied for:
Growth hormone signaling — how the pituitary responds to GHRH-like activity
IGF-1 pathways — how growth hormone signaling influences IGF-1-related activity
Longer peptide activity — how DAC extends the active research window
Pituitary response — how the pituitary releases growth hormone in research settings
Recovery research — pathways connected to repair, restoration, and rebuilding
Fat metabolism — pathways connected to how stored energy is processed
Body-composition research — markers related to lean mass, fat mass, and energy balance
CJC-1295 with DAC has been studied because the DAC modification extends its half-life and supports longer-duration GHRH-like signaling. In published research, CJC-1295 produced dose-dependent increases in mean growth hormone concentrations for 6 days or more and IGF-1 concentrations for 9–11 days after a single administration. Another study reported that pulsatile growth hormone secretion persisted during continuous stimulation by CJC-1295.
For research use only. Not for human consumption, medical use, diagnostic use, or therapeutic application.